Intravitreal anti-VEGF agents such as avastin, lucentis and macugen with wet macular degeneration. (Christoforidis) The project of radiolabeling of anti-VEGF agents was actively continued these past 12 months. The results of the work have received national and international attention as this new method provides a completely novel method to determine the pharmacokinetic properties of intravitreally placed agents. The initial phase of the study was submitted and recently published in our most esteemed eye research journal, Investigative Ophthalmology & Visual Science (early edition June 17, 2011). The topic has been presented at the following meetings:
1) ARVO, Fort Lauderdale, FL-May 1, 2011-Received Hot Topic Award, and
2) Aegean Retina Meeting-Rethymnon, Crete-July 8, 2011.